A breakthrough innovation from the University of Saskatchewan may lead to a shorter calving season for beef producers, reducing labor-intensive tasks. The hormone drug, Cetrorelix, traditionally used in human IVF treatments, has shown great potential for use in cattle reproduction. Dr. Jaswant Singh, along with graduate students Dylan Farmer and Carlos Leonardi, discovered the drug’s efficacy in synchronizing ovulation in cows, leading to simultaneous pregnancies and births.
This method, while not the first of its kind, could prove to be the most effective in managing calving periods, potentially reducing labor costs and improving animal management practices. The drug’s application could also enhance artificial insemination as a breeding method, offering benefits in genetic selection and calf production predictions.
Garner Deobald, a beef rancher and marketing manager at BoviGen Genetic Services, expressed keen interest in incorporating Cetrorelix into their operations, highlighting its potential benefits for both their own cattle and clients. The University of Saskatchewan has applied for a patent on the drug and is collaborating with pharmaceutical companies to bring it to market, aiming to revolutionize cattle breeding practices globally.
Dr. Singh is optimistic about the drug’s future adoption, emphasizing its promising results and affordability for livestock producers. With regulatory hurdles mostly cleared, the focus now lies on further testing and implementation in animals. The potential widespread use of Cetrorelix could lead to increased adoption of artificial insemination practices, benefitting farmers worldwide.
